Below is the product datasheet. This has been provided by the manufacturer and should always be provided with the medication. Introduction 
Company name: Dechra Veterinary Products Limited
Address: (A business unit of Dechra Pharmaceuticals PLC)
Sansaw Business Park
Hadnall, Shrewsbury
Shropshire SY4 4AS
Telephone: 01939 211200
Fax: 01939 211201
Email: info@dechra-uk.com
Website: www.dechra.com
Presentation
A fine white odourless powder for oral administration to horses presented in 5 g sachets, each sachet containing:
Active substance: Phenylbutazone 1 g
Uses
Pro-Dynam® is a non-steroidal anti-inflammatory drug (NSAID) for use in horses. It is indicated for the treatment of musculo-skeletal conditions where relief from pain and a reduction in the associated inflammation is required, e.g. in lameness associated with osteoarthritic conditions, bursitis, laminitis and soft tissue inflammation, particularly where continued mobility is considered desirable.
It is also of value in limiting post-surgical inflammation, myositis and other soft tissue inflammation.
Pro-Dynam® can be used as an anti-pyretic where this is considered advisable, e.g. in viral respiratory infections.
Dosage and administration
Pro-Dynam® should be administered by mouth.
For each 450 kg (1000 lb) body weight the following dosage guide should be used according to individual response:
Day 1
Two sachets twice daily (equivalent to 4.4 mg/kg on each occasion).
Days 2-4
One sachet twice daily (equivalent to 2.2 mg/kg on each occasion); followed by one sachet daily (2.2 mg/kg daily) or on alternate days as required.
If no response is evident after 4-5 days, discontinue treatment.
Hay may delay the absorption of phenylbutazone and so the onset of a clinical effect. It is advisable not to feed hay immediately prior to, or during the administration of Pro-Dynam®.
For ease of administration Pro-Dynam® may be added to a quantity of bran or oats.
Advice on correct administration: The therapeutic index of phenylbutazone is low. Do not exceed the stated dose or the duration of treatment.
Contraindications, warnings, etc
Do not use in animals with known hypersensitivity to the active ingredient.
Use is contraindicated in animals suffering from cardiac, hepatic or renal disease, where there is the possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia or hypersensitivity to the product.
Do not administer other NSAIDs or glucocorticoids concurrently or within 24 hours of each other.
Special warnings: The clinical effects of phenylbutazone can be evident for at least three days following cessation of therapy. This should be borne in mind when examining horses for soundness.
Some equestrian authorities regard phenylbutazone as a 'prohibited substance' within their rules.
Special precautions for use in animals: Do not exceed the stated dose as the therapeutic index of phenylbutazone is low.
Use in any animal less than 6 weeks of age or in aged animals may involve additional risk. If such use cannot be avoided, animals may require careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal as there is a potential risk of increased renal toxicity.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infections, appropriate concurrent antimicrobial therapy should be instigated.
Adverse reactions: In common with other NSAIDs that inhibit prostaglandin synthesis, there may be gastric and/or renal intolerance. This is usually associated with overdosage and such events are rare. Recovery is usual on cessation of treatment and following initiation of supportive symptomatic therapy, (see 'Overdose' section for further information).
If you notice any serious effects or other effects not mentioned in the data sheet, please inform your veterinary surgeon.
Use during pregnancy and lactation: Pregnancy: Care should be exercised if administered to pregnant mares. Although no adverse effects of phenylbutazone on the foetus or maintenance of pregnancy have been reported during field use, no definitive safety studies have been carried out in the mare.
Foetotoxic effects of phenylbutazone have been recorded in experimental animal species at high dose levels. Avoid use around time of parturition.
Lactation: Phenylbutazone does not readily cross the blood milk barrier.
If the administration of phenylbutazone to pregnant or lactating mares is considered essential, the potential benefits should be weighed against the potential hazard to the mare and/or foal. Avoid use around time of parturition.
Interaction with other medicinal products and other forms of interaction: Concurrent administration of potential nephrotoxic drugs should be avoided.
Phenylbutazone is extensively bound to plasma proteins. It may displace other drugs that are highly protein bound, e.g. some sulphonamides, warfarin, or it may itself be displaced to produce an increase in non-bound pharmacologically active concentrations, which can lead to toxic effects.
Concurrent therapy with other therapeutic agents should be undertaken with caution due to the risk of metabolic interactions. Phenylbutazone may interfere with the metabolism of other drugs, e.g. warfarin, barbiturates, with resultant toxicity.
There is evidence to indicate that the pharmacokinetics of penicillin products may be affected by concurrent administration of products containing phenylbutazone, with a possible reduction of therapeutic efficacy, since tissue penetration may be reduced. The distribution of other drugs given concurrently may also be affected.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infections, appropriate concurrent antimicrobial therapy should be instigated.
Overdose: Overdosing may result in gastric and large intestinal ulceration and general enteropathy. Renal papillary damage may also occur with impaired renal function. Subcutaneous oedema, especially under the jaw, may become evident due to plasma protein loss. There is no specific antidote. If signs of possible overdosage occur, treat the animal symptomatically.
Incompatibilities: None known.
Special precautions to be taken by the person administering the veterinary medicinal product to animals: Wash hands after use.
Avoid contact with the eyes. In case of accidental eye contact, irrigate eyes with plenty of clean water. If irritation persists seek medical advice.
Care should be taken to avoid inhaling or ingesting the powder. In the event of accidental inhalation or ingestion seek medical advice and show the product packaging.
General precautions: For animal treatment only.
Keep out of the reach and sight of children.
Withdrawal period: Not for use in horses intended for human consumption. Treated horses may never be slaughtered for human consumption. The horse must have been declared as not intended for human consumption under national horse passport legislation.
Pharmaceutical precautions
This veterinary medicinal product does not require any special storage conditions.
Do not use after the expiry date which is stated on the carton.
Disposal: Any unused product or waste material should be disposed of in accordance with guidance from your local waste regulation authority.
Legal category
POM-V
Packaging quantities
Boxes of 100 × 5 g sachets, each sachet containing 1 g phenylbutazone.
Further information
To be supplied only on veterinary prescription.
Veterinary medicinal product authorised for use in UK and IE.
Marketing authorisation holder (if different from distributor)
Dechra Veterinary Products A/S, Mekuvej 9, DK-7171 Uldum, Denmark.
Marketing authorisation number
Vm 24883/4000.
| 
